152 related articles for article (PubMed ID: 29332581)
1. Cetuximab and the Head and Neck Squamous Cell Cancer.
Concu R; Cordeiro MNDS
Curr Top Med Chem; 2018; 18(3):192-198. PubMed ID: 29332581
[TBL] [Abstract][Full Text] [Related]
2. [Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell cancer].
Vladimirova LY; Agieva AA; Engibaryan MA
Vopr Onkol; 2015; 61(4):580-2. PubMed ID: 26571826
[TBL] [Abstract][Full Text] [Related]
3. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices.
Peria M; Donnadieu J; Racz C; Ikoli JF; Galmiche A; Chauffert B; Page C
Head Neck; 2016 Apr; 38 Suppl 1():E911-5. PubMed ID: 25994489
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
[TBL] [Abstract][Full Text] [Related]
6. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
7. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
8. Emergence of long-term surviving patients with the introduction of Cetuximab in recurrent/metastatic disease of squamous cell carcinoma of head and neck.
Linares J; Rullan A; Taberna M; Vazquez S; Mesia R
Oral Oncol; 2016 Apr; 55():e4. PubMed ID: 26924081
[No Abstract] [Full Text] [Related]
9. Emerging drugs for head and neck cancer.
Wen Y; Grandis JR
Expert Opin Emerg Drugs; 2015 Jun; 20(2):313-29. PubMed ID: 25826749
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.
Blasco MA; Svider PF; Raza SN; Jacobs JR; Folbe AJ; Saraf P; Eloy JA; Baredes S; Fribley AM
Laryngoscope; 2017 Nov; 127(11):2565-2569. PubMed ID: 28581126
[TBL] [Abstract][Full Text] [Related]
11. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
[TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
Panikkar RP; Astsaturov I; Langer CJ
Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
[TBL] [Abstract][Full Text] [Related]
14. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
15. Are anti-vitamin K drugs contraindicated with cetuximab during head-and-neck cancer concomitant radiotherapy?
Brohée D; Henry AR; Castadot P
Acta Clin Belg; 2013; 68(3):237-9. PubMed ID: 24156231
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer.
Cancer Biol Ther; 2006 Apr; 5(4):340-2. PubMed ID: 16808060
[No Abstract] [Full Text] [Related]
17. A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck.
Chun SG; Hughes R; Sumer BD; Myers LL; Truelson JM; Khan SA; Ma TW; Xie Y; Yordy JS; Cooley S; Wu J; Choy H; Nedzi LA
Cancer Invest; 2017 Jan; 35(1):23-31. PubMed ID: 27892728
[TBL] [Abstract][Full Text] [Related]
18. Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer.
Bussmann L; Busch CJ; Lörincz BB; Rieckmann T; Block A; Knecht R
Eur Arch Otorhinolaryngol; 2016 Dec; 273(12):4073-4080. PubMed ID: 26755047
[TBL] [Abstract][Full Text] [Related]
19. Intra-arterial cetuximab for the treatment of recurrent unresectable head and neck squamous cell carcinoma
Tham T; White TG; Chakraborty S; Lall RR; Ortiz R; Langer DJ; Shatzkes D; Filippi CG; Kraus D; Boockvar JA; Costantino PD
J Exp Ther Oncol; 2016 Nov; 11(4):293-301. PubMed ID: 27849340
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
